Difluoropine has some stimulant effects in animals, although it is significantly less powerful than many of the potent phenyltropane derived stimulant drugs such as WIN 35,428 and RTI-55. It showed promising effects in alleviating the symptoms of Parkinson's Disease in an animal model of the disorder.
^Meltzer, PC; Liang, AY; Madras, BK (1994). "The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites". Journal of Medical Chemistry37 (13): 2001–10. doi:10.1021/jm00039a014. PMID8027983.
^Campbell, VC; Kopajtic, TA; Newman, AH; Katz, JL (2005). "Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs". The Journal of Pharmacology and Experimental Therapeutics315 (2): 631–40. doi:10.1124/jpet.105.090829. PMID16055673.
^Katz, JL; Izenwasser, S; Kline, RH; Allen, AC; Newman, AH (1999). "Novel 3alpha-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine". The Journal of Pharmacology and Experimental Therapeutics288 (1): 302–15. PMID9862785.
^Madras, BK; Fahey, MA; Goulet, M; Lin, Z; Bendor, J; Goodrich, C; Meltzer, PC; Elmaleh, DR et al. (2006). "Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo". The Journal of Pharmacology and Experimental Therapeutics319 (2): 570–85. doi:10.1124/jpet.106.105312. PMID16885433.